ES2150993T3 - Analogos de l-2',3'-didesoxi nucleosidos utilizados como agentes anti-hepatitis b (vhb) y anti-vih. - Google Patents

Analogos de l-2',3'-didesoxi nucleosidos utilizados como agentes anti-hepatitis b (vhb) y anti-vih.

Info

Publication number
ES2150993T3
ES2150993T3 ES94919207T ES94919207T ES2150993T3 ES 2150993 T3 ES2150993 T3 ES 2150993T3 ES 94919207 T ES94919207 T ES 94919207T ES 94919207 T ES94919207 T ES 94919207T ES 2150993 T3 ES2150993 T3 ES 2150993T3
Authority
ES
Spain
Prior art keywords
hbv
present
analogs
hepatitis
didesoxi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94919207T
Other languages
English (en)
Inventor
Tai-Shun Lin
Yung-Chi Cheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Application granted granted Critical
Publication of ES2150993T3 publication Critical patent/ES2150993T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL DESCUBRIMIENTO DE CIERTOS ANALOGOS DE DIDEOXINUCLEOSIDOS QUE CONTIENEN UNA UNIDAD DIDEOXI RIBOFURANOSILILO QUE TIENE UNA CONFIGURACION EN L (OPUESTA A LA CONFIGURACION EN D QUE SE DA DE MODO NATURAL) EXHIBEN ACTIVIDAD INESPERADA CONTRA EL VIRUS DE LA HEPATITIS B (HHBV).EN PARTICULAR, EL COMPUESTO DE ACUERDO CON LA PRESENTE INVENCION MUESTRAS UNA POTENTE INHIBICION DE LA DUPLICACION DEL VIRUS EN COMBINACION CON UNA TOXICIDAD MUY BAJA EN LA CELULAS HUESPED (POR EJEMPLO TEJIDO ANIMAL O HUMANO). LOS COMPUESTOS DE ACUERDO CON LA PRESENTE INVENCION MUESTRA UN UTILIDAD PRIMARIA COMO AGENTES PARA LA INHIBICION DEL CRECIMIENTO O DUPLICACION DE HBV, VIH Y OTROS RETROVIRUS, PREFERENTEMENTE HBV. EL COMPUESTO 1{(2,2-DIDEOXI-BETA-L-RIBOFURANOSIL)}-5-FLUOROCITOSINA SE PRESENTA POR TENER UN POTENTE AGENTE ANTIVIH CON BAJA TOXICIDAD EN CELULAS HUESPEDES.
ES94919207T 1993-05-25 1994-05-23 Analogos de l-2',3'-didesoxi nucleosidos utilizados como agentes anti-hepatitis b (vhb) y anti-vih. Expired - Lifetime ES2150993T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6729993A 1993-05-25 1993-05-25
US08/098,650 US5627160A (en) 1993-05-25 1993-07-28 L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents

Publications (1)

Publication Number Publication Date
ES2150993T3 true ES2150993T3 (es) 2000-12-16

Family

ID=26747712

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94919207T Expired - Lifetime ES2150993T3 (es) 1993-05-25 1994-05-23 Analogos de l-2',3'-didesoxi nucleosidos utilizados como agentes anti-hepatitis b (vhb) y anti-vih.

Country Status (14)

Country Link
US (1) US5627160A (es)
EP (1) EP0707481B1 (es)
JP (2) JPH08510747A (es)
KR (1) KR100279953B1 (es)
CN (1) CN1076021C (es)
AT (1) ATE195423T1 (es)
CA (1) CA2163520C (es)
DE (1) DE69425574T2 (es)
DK (1) DK0707481T3 (es)
ES (1) ES2150993T3 (es)
GR (1) GR3034379T3 (es)
HK (1) HK1013257A1 (es)
PT (1) PT707481E (es)
WO (1) WO1994027616A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6346627B1 (en) 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
EP0717628A4 (en) * 1993-09-10 1999-05-26 Univ Emory NUCLEOSIDES ACTIVATED AGAINST HEPATITIS B VIRUS
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5512431A (en) * 1994-06-29 1996-04-30 Darwin Molecular Corporation Methods of screening for nucleoside analogs that are incorporated by HIV reverse transcriptase and cause incorrect base pairing
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
WO1996028162A1 (en) * 1995-03-14 1996-09-19 University Of Medicine & Dentistry Of New Jersey New drug combination for the treatment of viral diseases
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
ATE346651T1 (de) 1995-06-07 2006-12-15 Univ Emory Nucleoside mit anti-hepatitis b virus wirksamkeit
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
EP1132393B1 (en) * 1996-10-16 2003-04-09 ICN Pharmaceuticals, Inc. L-Ribavirin and uses thereof
US6509320B1 (en) * 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
PL187107B1 (pl) * 1996-10-16 2004-05-31 Icn Pharmaceuticals L-nukleozydy monocykliczne, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie
KR100412480B1 (ko) * 1996-10-16 2003-12-31 아이씨엔 파마슈티컬스, 인코포레이티드 푸린 ｌ-누클레오시드, 이의 유사체 및 이들의 용도
US6090602A (en) 1998-02-18 2000-07-18 Promelas Research Corporation Levo-monosaccharide in a nucleoside analog for use as an anti-retroviral agent
DK2415776T3 (en) * 1998-08-10 2016-07-04 Novartis Ag Beta-L-2'-deoxy nucleosides for the treatment of Hepatitis B
US7635690B2 (en) 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7115584B2 (en) * 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US6525191B1 (en) * 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
AU2002255707A1 (en) 2001-03-15 2002-10-03 Trustees Of Boston College, The Selective anti-viral nucleoside chain terminators
EP1495040A4 (en) * 2002-04-12 2006-01-25 Achillion Pharmaceuticals Inc PROCESS FOR THE SYNTHESIS OF BETA-L-FLUORO-2 ', 3'-DIDEOXY-DIDEHYDROCYTIDINE (BETA-L-FD4C)
US20040067877A1 (en) * 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
EP1668023A1 (de) * 2003-09-12 2006-06-14 Max-Delbrück-Centrum Für Molekulare Medizin B-l-nucleoside und ihre verwendung als pharmazeutische mittel zur behandlung viraler erkrankungen
EP1802315A2 (en) 2004-10-19 2007-07-04 Achillion Pharmaceuticals, Inc. Combination therapy for treating viral infections
GB0513835D0 (en) * 2005-07-07 2005-08-10 Medivir Ab HIV inhibitors
EP2159224B1 (en) 2007-06-18 2012-08-01 Sunshine Lake Pharma Co., Ltd Bromo-phenyl substituted thiazolyl dihydropyrimidines
US8816074B2 (en) * 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
CN102666562A (zh) * 2009-12-17 2012-09-12 诺威戴克斯医药公司 新颖的3’-脱氧-3‘-亚甲基-β-L-核苷
CN102234280B (zh) * 2010-04-26 2014-01-08 北京大学 D,l-鸟嘌呤核苷类似物及其制备方法和应用
EP3543238B1 (en) 2016-11-16 2021-05-19 National Center for Global Health and Medicine Nucleoside derivatives having anti-viral activity
KR102077833B1 (ko) 2018-12-10 2020-02-14 류형준 기능성 식품조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817982A (en) * 1971-12-29 1974-06-18 Syntex Inc 2{40 ,3{40 -unsaturated nucleosides and method of making
DE3689976T2 (de) * 1985-05-15 1995-03-16 Wellcome Found Therapeutische Nucleoside und deren Herstellung.
JPS62501712A (ja) * 1985-08-26 1987-07-09 アメリカ合衆国 ２′、３′―ジデオキシイノシン、２′，３′―ジデオキシグアノシンまたは２′，３′―ジデオキシアデノシンを含有する抗ｈｔｌｖ―３／ｌａｖ剤
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
SE8602981D0 (sv) * 1986-07-04 1986-07-04 Astra Laekemedel Ab Novel medicinal use
US4788181A (en) * 1986-09-29 1988-11-29 The United States Of America As Represented By The Department Of Health And Human Services 5-substituted-2',3'-dideoxycytidine compounds with anti-HTLV-III activity
IL85778A0 (en) * 1987-03-20 1988-09-30 Bristol Myers Co Production of 2',3'-dideoxynucleosides and certain such novel compounds
JPH01100191A (ja) * 1987-10-13 1989-04-18 Sanyo Kokusaku Pulp Co Ltd ２′，３′−ジデオキシシチジン類の製造方法
SE8704298D0 (sv) * 1987-11-03 1987-11-03 Astra Ab Compounds for use in therapy
US4997926A (en) * 1987-11-18 1991-03-05 Scripps Clinic And Research Foundation Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy
JPH07103149B2 (ja) * 1987-11-30 1995-11-08 ヤマサ醤油株式会社 シトシン誘導体の製造法
JPH02152976A (ja) * 1988-05-06 1990-06-12 Bristol Myers Co ２´，３´―ジデヒドロ―２´，３´―ジデオキシヌクレオシドのプロドラッグ
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
JPH0269476A (ja) * 1988-09-06 1990-03-08 Kohjin Co Ltd ピリミジン誘導体の製法
DD293498A5 (de) * 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
US5128458A (en) * 1990-04-20 1992-07-07 Southern Research Institute 2',3'-dideoxy-4'-thioribonucleosides as antiviral agents
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
CA2135498A1 (en) * 1992-05-13 1993-11-25 Leonid Beigelman Synthesis of nucleotide monomers
DE4224737A1 (de) * 1992-07-27 1994-02-03 Herbert Prof Dr Schott Neue Cytosinnucleosidanaloga, Verfahren zu ihrer Herstellung und ihre Verwendung
CA2105112C (en) * 1992-09-01 2005-08-02 Thomas C. Britton A process for anomerizing nucleosides
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues

Also Published As

Publication number Publication date
CN1100303A (zh) 1995-03-22
JPH08510747A (ja) 1996-11-12
HK1013257A1 (en) 1999-10-22
JP2004244422A (ja) 2004-09-02
KR100279953B1 (ko) 2001-02-01
US5627160A (en) 1997-05-06
DE69425574D1 (en) 2000-09-21
EP0707481B1 (en) 2000-08-16
EP0707481A4 (es) 1996-05-29
DE69425574T2 (de) 2001-01-04
EP0707481A1 (en) 1996-04-24
CA2163520A1 (en) 1994-12-08
DK0707481T3 (da) 2000-10-30
WO1994027616A1 (en) 1994-12-08
CA2163520C (en) 2006-01-10
ATE195423T1 (de) 2000-09-15
PT707481E (pt) 2001-02-28
AU693795B2 (en) 1998-07-09
GR3034379T3 (en) 2000-12-29
CN1076021C (zh) 2001-12-12
AU7043094A (en) 1994-12-20

Similar Documents

Publication Publication Date Title
ES2150993T3 (es) Analogos de l-2',3'-didesoxi nucleosidos utilizados como agentes anti-hepatitis b (vhb) y anti-vih.
TW374087B (en) L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
EP0287313A3 (en) Acid stable dideoxynucleosides active against the cytopathic effects of human immunodeficiency virus
KR900004735A (ko) 시클로부탄 유도체 및 그 제조방법
ATE328889T1 (de) L-nukleoside zur behandlung des hepatitis-b- und epstein-bar-virus
PA8483101A1 (es) Compuestos quimicos
BR9815166A (pt) "método de inibição da replicação de vìrus, composto, método de inibição da replicação de citomegalovìrus, composto antiviral, utilização de um composto, composição farmacêutica, composição farmacêutica inibidora da replicação de vìrus e de citomegalovìrus e composição farmacêutica antiviral"
ES2009168A6 (es) Procedimiento de obtencion de 3'-azido-2',3'-dideoxiuridina anti-retroviral.
MD950086A (ro) Utilizare a analogilor nucleozidici ai 1,3-oxatiolanei in tratamentul hepatitei B Use of 1,3-oxathiolan nucleoside analogues in the treatment of hepatitis B
KR890003761A (ko) 치료학적 아시클릭 뉴클레오시드
ES2022883B3 (es) Una composicion desodorante y uso de ella
AU4408597A (en) Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof
KR910000734A (ko) 네플라노신 유도체
IE893991L (en) 2',3'-dideoxypurine nucleoside/purine nucleoside¹phosphorylase inhibitor combination therapy and composition
ES8605538A1 (es) Procedimiento para la preparacion de nonapeptidos y dodecapeptidos
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
DE69731483D1 (de) Beta-l-dioxolanuridin-analoge zur behandlung und vorbeugung von durch ebv, vzv bzw. hv-8 verursachten viralen infektionen
KR900701763A (ko) 1-아미노-5-할로게노우라실, 그의 제조방법 및 이 화합물을 유효성분으로 함유하는 중추신경억제제
FR2591890B1 (fr) Composition a usage therapeutique comprenant des composes organo-silicies
SE9701912D0 (sv) Pharmaceutical composition and use thereof
WO1986001716A1 (en) Use of pyrrothine derivatives
KR900002787A (ko) 인체 후천성 면역부전증후군 바이러스 감염 저해제
DE69930678D1 (de) Azidoderivate von beta-l-2'-nukleosiden zur hiv-infektionsbehandlung
ES2116522T3 (es) Compuestos citotoxicos.
ES2078139B1 (es) Composiciones antirretrovirales que contienen compuestos iodados.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 707481

Country of ref document: ES